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Abstract
Background: Noonan syndrome (NS), a heterogeneous developmental disorder associated with variable clinical
expression including short stature, congenital heart defect, unusual pectus deformity and typical facial features, is
caused by activating mutations in genes involved in the RAS-MAPK signaling pathway.
Case presentation: Here, we present a clinical and molecular characterization of a small family with Noonan
syndrome. Comprehensive mutation analysis of NF1, PTPN11, SOS1, CBL, BRAF, RAF1, SHOC2, MAP2K2, MAP2K1,
SPRED1, NRAS, HRAS and KRAS was performed using targeted next-generation sequencing. The result revealed a
recurrent mutation in NRAS, c.179G > A (p.G60E), in the index patient. This mutation was inherited from the index
patient’s father, who also showed signs of NS.
Conclusions: We describe clinical features in this family and review the literature for genotype-phenotype
correlations for NS patients with mutations in NRAS. Neither of affected individuals in this family presented with
juvenile myelomonocytic leukemia (JMML), which together with previously published results suggest that the risk for
NS individuals with a germline NRAS mutation developing JMML is not different from the proportion seen in other NS
cases. Interestingly, 50 % of NS individuals with an NRAS mutation (including our family) present with lentigines and/or
Café-au-lait spots. This demonstrates a predisposition to hyperpigmented lesions in NRAS-positive NS individuals. In
addition, the affected father in our family presented with a hearing deficit since birth, which together with lentigines
are two characteristics of NS with multiple lentigines (previously LEOPARD syndrome), supporting the difficulties in
diagnosing individuals with RASopathies correctly. The clinical and genetic heterogeneity observed in RASopathies is a
challenge for genetic testing. However, next-generation sequencing technology, which allows screening of a large
number of genes simultaneously, will facilitate an early and accurate diagnosis of patients with RASopathies.
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Background
Noonan syndrome (NS, OMIM 163950) is a relatively
common developmental disorder belonging to the
RASopathies, a group of clinically and genetically related
syndromes [1, 2]. The molecular cause underlying
RASopathies is dysregulation of the RAS-MAPK path-
way and 15 different genes affecting this pathway have
been associated to RASopathies. Of these 15 genes,
eleven have been found to be involved in NS or NS-like
conditions, where mutations in PTPN11 are the cause of
~50 % of the cases. The other genes are SOS1 [3, 4], CBL
[5–7], BRAF [8], RAF1 [9, 10], SHOC2 [11], MAP2K1
[12], RIT1 [13], NRAS [14], KRAS [15, 16] and RRAS [17].
The main characteristics of NS are short stature,
congenital heart defect, unusual pectus deformity and
typical facial features, such as hypertelorism, ptosis,
down-slanting palpebral fissures, low-set posteriorly ro-
tated ears and a broad forehead. However, NS is a clinic-
ally variable disorder and additional associated features
often present include neonatal failure to thrive, mild
mental retardation, various skin manifestations, bleeding
abnormalities and multiple skeletal defects [18, 19].
NRAS is a four-exon gene, encoding the widely
expressed small GTPase NRAS, which act as a membrane-
associated molecular switch in the RAS-MAPK pathway
[14]. To date, only eight unrelated individuals with NS and
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three NS families have been identified with mutations in
NRAS [14, 20–23].
Here, we performed a comprehensive molecular ana-
lysis of 13 RASopathy-associated genes; NF1, PTPN11,
SOS1, CBL, BRAF, RAF1, SHOC2, MAP2K2, MAP2K1,
SPRED1, NRAS, HRAS and KRAS, in a family with NS,
which revealed a previously reported mutation in NRAS,
c.179G > A (p.G60E). We describe clinical features in
this family and review the literature for genotype-
phenotype correlations for NS patients with mutations
in NRAS.
Case presentation
Clinical investigations and genetic analyses were
performed according to the guidelines in the Declaration
of Helsinki and approved by the ethical committee of
Uppsala University and Gothenburg University, Sweden.
Informed consent was obtained from all patients and
specific permission was given for photographs.
Case 1
This is a 28-year-old woman, who got the clinical diag-
nosis of Noonan syndrome (NS) at the age of 4 years
because of growth retardation, cardiomyopathy and fa-
cial features. She is the only child of non-related parents.
The father (Case 2) has facial features of NS, but few
additional clinical symptoms. She was born to a mother
with diabetes during pregnancy with a birth weight of
4.7 kg (+3 SDS), a length of 52 cm (+1 SDS) and a head
circumference of +2 SDS. She also had a large left ven-
tricle, and a systolic murmur, but this disappeared at the
age of six years. Postnatally, her growth decelerated and
she had feeding difficulties. At 6.5 years of age, her height
was 104 cm (−2 SDS) and her weight 18.5 kg (−2 SDS).
Fig. 1 Photograph of the index patient affected by NS with a mutation in NRAS, p.G60E. a Facial features. b The back with multiple lentigines. c
The left arm with multiple lentigines
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She had low endogenous growth hormone (GH) secretion
defined as “partial GH deficiency”, and started GH therapy
within a formal clinical trial (NovoNordisk) from 6.5 years
of age. She was treated with GH (dose of 66 μg/kg/day)
and responded exceptionally well and treatment was dis-
continued after two years. However, at 10 years of age, she
had her first pubertal signs and GH-treatment was started
again using a standard dose of 33 μg/kg/day. At 12.3 years
of age, she had menarche. The GH-treatment continued
until final height (FH) was reached at the age of 14 years.
Her FH is 164.5 cm (−0.45 SDS) and weight of 60 kg (+0.3
SDS). Her psychomotor development is normal, but she
has slight problems of attention deficit. She attended regu-
lar school and works as an assistant nurse. At the age of
24 years, she has the following features of NS (Fig. 1a): a
large skull (62 cm) with a broad forehead, hypertelorism,
down slanted palpebral fissures, bilateral ptosis (especially
of her left eye), short and broad neck with a low hairline,
and low-set ears with broad helices. Her hair is normal.
She has two large Café-au-lait spots on her back and >50
freckles (lentigines) all over her body, especially on her
back (Fig. 1b) and arms (Fig. 1c).
Case 2
This is the 62-year-old father of Case 1. He was clinically
diagnosed after Case 1 was diagnosed. He has facial
features of NS, but few additional clinical symptoms.
Sensorineural hearing impairment was present at birth.
His growth pattern was normal, but he had a delayed
puberty. His FH is 175.0 cm (−0.4 SDS) and weight
75 kg (±0 SDS). The intellectual development was
normal. He followed normal school and university edu-
cation and worked as a librarian until the age of 55 years,
when he had to retire because of tinnitus. At the age of
62 years, he has the following features of NS (Fig. 2a–c):
slight macrocephaly (61 cm, +2 SDS), bilateral ptosis,
hypertelorism and down-slanting palpebral fissures. He
Fig. 2 Photograph of the affected father with the same NRAS mutation, p.G60E. a Frontal facial features. b Additional facial features. c The back
with multiple lentigines
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also has curly hair and lentigines on his back. He had a car-
diac murmur in childhood that disappeared spontaneously.
Methods
Genomic DNA from the index patient and her father was
extracted from peripheral blood leukocytes according to
standard procedures.
Mutation analysis
The index patient was analyzed for variants in all coding
exons and exon-intron boundaries of NF1 (NM_00
0267.3), PTPN11 (NM_002834), SOS1 (NM_005633),
CBL (NM_005188), BRAF (NM_004333), RAF1 (NM_00
2880), SHOC2 (NM_007373), MAP2K2 (NM_030662),
MAP2K1 (NM_002755), SPRED1 (NM_152594), NRAS
(NM_002524), HRAS (NM_005343) and KRAS (NM_00
4985) using Agilent HaloPlex Target Enrichment (Agilent
Technologies, Inc., Santa Clara, CA, USA), followed by
next-generation sequencing on MiSeq, Illumina (Illumina,
Inc., San Diego, CA, USA). Data analysis was performed
by NextGENe software v2.3.1 (SoftGenetics, LLC., State
College, PA, USA) and BENCHlab NGS (Cartagenia, Inc.,
Cambridge, MA, USA) [Ekvall et al. Manuscript in
preparation].
Variants observed in NRAS exon 2 were verified by
bi-directional Sanger sequencing in the index patient
and her father. Primer sequences and PCR conditions
are available upon request.
Results
DNA sequencing analysis of the index patient (Fig. 1)
was performed on 13 RASopathy-associated genes
using HaloPlex target enrichment (Agilent) and next-
generation sequencing on MiSeq (Illumina). Coverage
and read depth of the RASopathy genes in the index
patient is shown in Table 1. Targeted bases in region
of interest (ROI) with >30X read depth was 100 %
for all genes, except NF1 (99.8 %) and SOS1 (99.9 %).
No complementary Sanger sequencing was performed.
A heterozygous missense mutation, c.179G > A;
p.G60E, in exon 2 of NRAS was identified and veri-
fied using Sanger sequencing. This mutation was
inherited from the father (Fig. 2), who also shows
signs of NS. No additional variants of significance
were identified in the index patient.
Conclusions
To date, only eight unrelated patients with NS and three
NS families have been reported positive for NRAS
mutations (p.G13D, p.I24N, p.P24L, p.T50I and p.G60E)
[14, 20–23]. In this study, we describe an additional fam-
ily with NS, where the index patient and her father have
c.179G > A (p.G60E). This mutation has been identified
in both sporadic and familial NS patients of European
origin [14, 23] and is the most common germline
mutation in NRAS.
NS patients with NRAS mutations often show a rela-
tively mild phenotype of typical Noonan facial features. A
comparison of previously reported NRAS-associated NS
cases shows that all of the patients present with typical
Noonan facial features (14/14) and 11/13 have macro-
cephaly or relative macrocephaly, but only half of them
display congenital heart defects (7/14). All previously re-
ported patients also show short stature. However, in the
family reported here the father’s height was normal, while
the daughter had short stature successfully treated with
GH. The majority has pterygium or webbing of the neck
(10/12). Thorax deformity (pectus excavatum) occurs in
5/14 patients, while easy bruising is less common (3/14).
Half of the males show cryptorchidism (6/10) and oph-
thalmological problems appear in 4/14 patients. Motor
delay is common (9/14 patients) and as previously re-
ported, intellectual development is often mildly delayed (6
patients normal and 8 mildly delayed). Keratosis pilaris/
hyperkeratosis is less common (4/12 patients) and hair
abnormalities occur in about half of the patients. Of
note, lentigines are observed in six patients, but leukemia/
cancer are rarely seen (1 patient with JMML) (Table 2)
[14, 20–23]. Somatic mutations affecting genes in the
RAS-MAPK pathway are associated with cancer, and NS
and related disorders are known to cause a predisposition
to cancer [24]. Somatic mutations in NRAS are involved in
the development of hematological malignancies and in a
variety of solid tumors (COSMIC database; http://cancer.-
sanger.ac.uk/). However, germline NRAS mutations differ
from most common somatic NRAS mutations associated
Table 1 Average read depth and coverage of RASopathy-
associated genes in this study
Gene Reference
sequence
ROIa
bases
Exons Average
read depth
Coverage
>30X (%)
BRAF NM_004333 3021 18 12 637 100. 0
CBL NM_005188 3361 16 12 016 100.0
HRAS NM_005343 812 6 14 291 100.0
KRAS NM_004985 768 5 10 811 100.0
MAP2K1 NM_002755 1622 11 12 525 100.0
MAP2K2 NM_030662 1643 11 11 127 100.0
NF1 NM_000267 10737 58 12 728 99.8
NRAS NM_002524 861 7 16 378 100.0
PTPN11 NM_002834 6521 16 16 262 100.0
RAF1 NM_002880 2587 16 15 985 100.0
SHOC2 NM_007373 2069 8 17 812 100.0
SOS1 NM_005633 4922 23 13 439 99.9
SPRED1 NM_152594 1615 7 10 509 100.0
aROI Region of interest
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Table 2 Clinical features of patients with Noonan syndrome caused by NRAS mutations
# 1 2 3 4 5 6 7 8
Patient De Filippi et al.
[20]
Runtuwene et al. [21] Denayer et al. [22] Denayer et al. [22] Denayer et al. [22] Cirstea et al. [14] Cirstea et al. [14] Cirstea et al. [14]
NRAS mutation p.G13D p.I24N p.I24N p.P24L p.T50I p.T50I p.T50I p.G60E
Origin of mutation de novo de novo de novo Inherited ND de novo de novo de novo
Paternal age at conception ND 26 years ND ND ND 50 years 34 years 31 years
Age at last examination 3 years 30 years 13 years 19 years 2.5 years 14 years 7 years 3.3 years
Gender Male Male Male Male Male Male Male Female
Prenatal findings ND Polyhydramnios ND ND ND Nuchal edema,
Polyhydramnios
Polyhydramnios Single umbilical
artery
Congenital heart defect - - - ND Coarctation aortae,
Patent foramen
ovale
HCM PS Mild HCM, Mitral
valve dysplasia,
PS
Rythm disturbance ND - ND ND - SVES - -
Typical facial features + + + + + + + +
Stature 5–10th centile Mild short <3rd centile 10th–25th centile 10th–25th centile 10th centilea <3rd centile <3rd centile
Macrocephaly Relative >90th centile >97th centile ND 25th–50th centile + Relative -
Pterygium colli/Webbed neck - + ND ND + + - +
Thorax deformity - Pectus excavatum Pectus excavatum ND Pectus excavatum + - Pectus excavatum
Easy bruising - - ND + ND - - -
Cryptorchidism - + + ND + + + NA
Ophthalmological problems ND - Strabismus, Bilateral
keratoconus of the
cornea
ND ND Myopia - -
Motor delay/Muscular hypotonia - Motor delay Mild ND ND Mild + +
Mental development Normal Mild learning
difficulties
Normal Learning difficulties Normal Normal Borderline Speech delay
Keratosis pilaris/Hyperkeratosis ND - ND ND ND Severe - +
Hair abnormalities - - ND ND ND Curly hair Curly hair Sparse thin hair
Lentigines/Café-au-lait spots + Some lentigines - - - - - -
Leukemia/Cancer JMML - - - - - - -
Other - Oligospermia - Inadequate visio-spatial
orientation skills, Inguinal
hernia, Delayed pubertal
development
- Pes equinovarus - Palpebral ptosis
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Table 2 Clinical features of patients with Noonan syndrome caused by NRAS mutations (Continued)
# 9 9 M 10 11 12 12 F
Patient Cirstea et al. [14] Cirstea et al. [14] Kraoua et al. [23] Kraoua et al. [23] Present study Present study
NRAS mutation p.G60E p.G60E p.G60E p.G60E p.G60E p.G60E
Origin of mutation Inherited ND ND (probably inherited) de novo Inherited ND (probably inherited)
Paternal age at conception 47 years 44 years 45 years 47 years 34 years ND
Age at last examination 20 years 50 years 24 years 3 months 28 years 62 years
Gender Male Female Male Female Female Male
Prenatal findings - - Polyhydramnios Pyelectasis - -
Congenital heart defect - - - PS ASD, HCM Cardiac murmur
Rythm disturbance - - - - - -
Typical facial features + + + + + +
Stature >10th centile 10th centile 3rd centile 3rd–10th centile 50th centilea 50th centile
Macrocephaly + + Relative Relative + Relative
Pterygium colli/Webbed neck + + + + + +
Thorax deformity + + Mildly depressed thorax Pectus excavatum - -
Easy bruising - - + ND + -
Cryptorchidism + NA - NA NA -
Ophthalmological problems - Myopia - - Astigmatis, Myopia,
Strabismus
-
Motor delay/Muscular hypotonia + + Mild + - -
Mental development Normal-borderline Normal Speech delay, dyscalculy NA ADHD, normal IQ Normal
Keratosis pilaris/Hyperkeratosis + + ND - - -
Hair abnormalities Curly hair - - Curly hair - Curly hair
Lentigines/Café-au-lait spots - - + + + +
Leukemia/Cancer - - - - - -
Other Ichtyosiform eczema,
Acanthosis nigricans,
Scoliosis
Mother of patient 9 Palpebral ptosis, Inguinal
hernia, Scoliosis
Palpebral ptosis,
Unilateral pyelectasis
- Sensory-neural hearing
deficit, Father of patient 12
ASD atrial septal defect, HCM hypertrophic cardiomyopathy, JMML juvenile myelomonocytic leukemia, NA not applicable, ND not determined, PS pulmonic stenosis, SVES supraventricular extrasystole
aReceived growth hormone treatment from the age of 8 years, when partial growth hormone deficiency had been noted
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with malignancies and are less activating in dysregulating
intracellular signaling [18].
In summary, we report an NS family with a p.G60E in
NRAS. Neither of affected individuals presented with
JMML. Thus, the proportion of JMML observed in
NRAS patients (1/12) is comparable with the observed
proportion of JMML in NS in general [25].
Interestingly, half of the patients (including affected
individuals in our family) presented with lentigines and/
or Café-au-lait spots, which is high compared to the
prevalence of 3 % for lentigines and 10 % for Café-au-lait
spots in the general NS population [26]. Multiple nevi,
lentigines and/or Café-au-lait spots are also detectable in
one-third of NS individuals with a RAF1 mutation and
previous studies have demonstrated a higher prevalence
of these features in BRAF-positive NS individuals as
well. This suggests that NS individuals with a mutation
in NRAS, RAF1 or BRAF have a predisposition to hyper-
pigmented cutaneous lesions [8, 27]. Of note, the father
in our family presented with congenital sensorineural
hearing impairment, which together with lentigines are
two common features in Noonan syndrome with multiple
lentigines (NS-ML, previously LEOPARD syndrome). This
demonstrates the wide spectrum of phenotypes within
each syndrome as well as the clinical overlap between
RASopathies, which makes diagnosis of NS and related
disorders challenging.
However, by using the advent of next-generation
sequencing technology, which allow for screening of a
large number of genes simultaneously, an early and
accurate genetic diagnosis of patients with RASopathies
will be facilitated.
Consent
We have obtained written informed consent from the pa-
tients for publication of this case report and accompany-
ing images. A copy of the written consent is available from
the Editor of this journal.
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